Evidence map›Paper›PMID 40388017›Full record

ArticleJournal of molecular modeling2025

Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9.

Nur Alya Amirah Azhar, Yung-An Chua, Hapizah Nawawi, Siti Azma Jusoh

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nur Alya Amirah AzharFaculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, 42300, Bandar Puncak Alam, Selangor, Malaysia.
Yung-An ChuaInstitute of Pathology, Laboratory and Forensic Medicine (I-PPerForm), Universiti Teknologi MARA, 47000, Sungai Buloh, Selangor, Malaysia.
Hapizah NawawiInstitute of Pathology, Laboratory and Forensic Medicine (I-PPerForm), Universiti Teknologi MARA, 47000, Sungai Buloh, Selangor, Malaysia.
Siti Azma JusohFaculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, 42300, Bandar Puncak Alam, Selangor, Malaysia. sitiazma@uitm.edu.my.

Funding

Universiti Teknologi MARA (UiTM) DUCS CoE Grant [600-UiTMSEL (PI. 5/4)(030/2022)]
6 · The paper itself

Abstract

contextThe low-density lipoprotein receptor (LDLR) regulates cholesterol uptake by mediating the hepatic clearance of plasma low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type-9 (PCSK9) attenuates LDLR function by binding to the LDLR, leading to its lysosomal degradation and preventing the total depletion of circulating LDL-C. However, pathogenic PCSK9 variants can reduce LDLR availability, significantly increase plasma LDL-C levels. Despite this understanding, the detailed molecular mechanism of LDLR-PCSK9 interaction remains unclear due to the incomplete LDLR structure. This study uses molecular dynamics (MD) simulations to predict LDLR structural dynamics upon binding to PCSK9. Furthermore, PCSK9 variants, E498A and R499G, that were identified in Malaysian FH patients were investigated for their mutational effects. Throughout the simulations, PCSK9 remained stable, while LDLR explored a larger conformational space. The LDLR-PCSK9 wild-type (WT) complex showed minimal changes, while the LDLR-PCSK9(R499G) complex exhibited pronounced conformational rearrangement. The MM/GBSA analysis revealed that the LDLR-PCSK9(E498A) complex had the highest binding affinity (- 63.81 kcal/mol), followed by the WT complex (- 33.07 kcal/mol), and LDLR-PCSK9(R499G) (- 24.21 kcal/mol). These findings offer novel insights into the dynamic interactions between LDLR and PCSK9, highlighting the role of structural flexibility in their relationship. Further MD simulation studies with the complete LDLR structure as well as experimental validation are needed to elucidate the molecular mechanisms underlying LDLR-PCSK9-mediated cholesterol homeostasis.

methodsThe initial structure of the wild-type (WT) LDLR-PCSK9 complex was obtained from PDB ID 3P5C, and the PCSK9 mutant structures (E498A and R499G) were modeled using the SPDBV program. MD simulations for each complex-LDLR-PCSK9 WT, LDLR-PCSK9(E498A), and LDLR-PCSK9(R499G)-were conducted using the GROMACS package with the CHARMM36m force field. The simulations were performed at 310.15 K with 2-fs timesteps under the isothermal-isobaric (NPT) ensemble, with each run lasting 500 ns. Including triplicates, the total duration of MD simulation time for all complexes amounted to 3.5 μs.

Indexed as

Proprotein Convertase 9Receptors, LDLCholesterol, LDLHumansHyperlipoproteinemia Type IIMolecular Dynamics SimulationProtein Interaction MappingProtein Structure, TertiarySoutheast Asian PeopleCholesterol, LDLPCSK9 protein, humanProprotein Convertase 9Receptors, LDLFamilial hypercholesterolemia (FH)Low-density lipoprotein cholesterol (LDL-C)Low-density lipoprotein receptor (LDLR)Molecular dynamics (MD) simulationsProprotein convertase subtilisin/kexin type-9 (PCSK9)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.